Wednesday, June 10, 2026

Patent intelligence Β· US

US 12533358

Methods of treatment with elinzanetant

granted A61K 31/ 5383 A IA61K/315383A61P 15/ 12 A IA61P/1512
Status granted
Linked drugs 2
Pipeline programs 6
Years to expiry 20
Applicant portfolio 25
Patent details β€” US 12533358
Jurisdiction
US
Status
granted
Grant date
Jan 27, 2026
Expiration
Jan 22, 2046
CPC classes
A61K 31/ 5383 A I, A61K/315383, A61P 15/ 12 A I, A61P/1512
View on Google Patents β†—

Quick answer

US 12533358 (Methods of treatment with elinzanetant) is held by BAYER CONSUMER CARE AG [CH]. Status: granted. Granted Jan 27, 2026. Expires Jan 22, 2046 (20 years remaining) β€” relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
β€”
CPC classes
A61K 31/ 5383 A I, A61K/315383, A61P 15/ 12 A I, A61P/1512

More from BAYER CONSUMER CARE AG [CH]

Related pharmaceutical patents in our USPTO index.

  1. WO 2026112109

    TECHNOLOGIE DE PLATEFORME DE GRANULATION PAR VOIE HUMIDE POUR FABRIQUER DES COMPRIMÉS/ARTICLES À MÂCHER MOUS

    BAYER HEALTHCARE LLC [US] Β· Expires May 23, 2046

    granted
  2. WO 2026106858

    FORMULATIONS ET PROCÉDÉS POUR MAINTENIR UNE SUSPENSION ET UNE VIABILITÉ DE CELLULES

    BAYER HEALTHCARE LLC [US] Β· Expires May 16, 2046

    granted
  3. EP 4741400

    MULTIMERE MANGANKONTRASTMITTEL

    BAYER AG [DE] Β· Expires May 8, 2046

    granted
  4. WO 2026068294

    PROCESSUS DE NANOENSEMENCEMENT AMÉLIORÉ

    BAYER AG [DE] Β· Expires Mar 28, 2046

    granted
  5. WO 2026047020

    FORMES CRISTALLINES D'INHIBITEURS DE HER2/MUTEGFR ET LEUR PROCÉDÉ DE PRÉPARATION

    BAYER AG [DE] Β· Expires Feb 28, 2046

    granted
  6. WO 2026047022

    FORME POSOLOGIQUE PHARMACEUTIQUE SOLIDE ET STABLE COMPRENANT UNE FORME CRISTALLINE D'UN INHIBITEUR DE HER2/MUTEGFR ET SA MÉTHODE DE PRÉPARATION

    BAYER AG [DE] Β· Expires Feb 28, 2046

    granted
  7. US 20260051027

    GENERATION OF SYNTHETIC CONTRAST-ENHANCED RADIOLOGICAL IMAGES

    BAYER AG [DE] Β· Expires Feb 14, 2046

    granted
  8. WO 2026032865

    SEL D'UN INHIBITEUR DE SOS-1

    BAYER AG [DE] Β· Expires Feb 7, 2046

    granted

Frequently asked questions

What is US patent 12533358?

US 12533358 (Methods of treatment with elinzanetant) is held by BAYER CONSUMER CARE AG [CH]. Status: granted. Granted Jan 27, 2026. Expires Jan 22, 2046 (20 years remaining) β€” relevant for patent-cliff and LOE planning.

Who owns US 12533358?

BAYER CONSUMER CARE AG [CH] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.

When does US 12533358 expire?

Our index shows an expiration date of Jan 22, 2046 (20 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.